Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients taking bisphosphonate therapy for symptomatic hypercalcemia within the past 28 days; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients taking bisphosphonate therapy for symptomatic hypercalcemia are NOT allowed; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
GENERAL: Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed.
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., osteoporosis) is allowed
Bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed.
Bisphosphonate therapy for symptomatic hypercalcemia a) Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients taking bisphosphonate therapy for symptomatic hypercalcemia\r\n* Note: use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Bisphosphonate therapy for symptomatic hypercalcemia (use of bisphosphonate therapy for other reasons [e.g., osteoporosis] is allowed.)
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Total calcium (corrected for serum albumin) within normal limits (ongoing requirement for bisphosphonate to control malignant hypercalcemia is not allowed but prophylactic use of bisphosphonate to prevent skeletal complication of bone metastasis is allowed)
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
Bisphosphonate therapy for symptomatic hypercalcemia
Bisphosphonate therapy for symptomatic hypercalcemia
Bisphosphonate therapy for symptomatic hypercalcemia
Bisphosphonate therapy for symptomatic hypercalcemia
Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy. Patients who are receiving bisphosphonate therapy specifically to prevent skeletal events and who do not have a history of clinically significant hypercalcemia are eligible.
Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab (bisphosphonate use for prevention of skeletal events allowed)